| alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. | None |
| The potential for targeting oncogenic WNT/beta-catenin signaling in therapy. | None |
| EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. | None |
| Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. | None |
| The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. | None |
| Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. | None |
| Oncogenic mutations of CTNNB1 were found in hepatoblastoma. Wnt/beta-catenin target genes were significantly activated in the tumors without mutations. The clinical course in patients without CTNNB1 mutations seemed to be unfavorable. | None |
| siRNA-mediated downregulation of beta-catenin could be valuable for defining gene expression and functional programs downstream of oncogenic beta-catenin signals. | None |
| H. pylori induced activation of NF-kappaB and AP-1, cell proliferation, and expression of oncogenes (beta-catenein, c-myc) in AGS cells, which was inhibited by transfection of MAD3 and TAM67. | None |
| Oncogenic beta-catenin and PI3K activities interact in the acquisition of multiple cancer-related phenotypes in organoids grown in Matrigel. | None |
| Beta-catenin as oncogene: the smoking gun. | None |